Bespoke Apothecary sold COVID kit and herbal tea with unapproved COVID-19 treatment claims, FDA and FTC say.
What happened
FDA reviewed the company's website on September 7, 2022, and the FTC reviewed it on September 26, 2022, along with linked Facebook and Instagram pages. The review found the COVID kit and Post Virus Recovery Herbal Tea offered for sale with claims to mitigate, prevent, treat, diagnose, or cure COVID-19. FDA calls the products unapproved new drugs and misbranded drugs.
What FDA found
The COVID kit and Post Virus Recovery Herbal Tea are unapproved new drugs because they are sold with claims to treat or prevent COVID-19 without FDA approval.
FD&C Act section 505(a), 21 U.S.C. § 355(a)The products are misbranded because their labeling makes misleading COVID-19 treatment and prevention claims.
FD&C Act section 502, 21 U.S.C. § 352Putting these products into interstate commerce is prohibited.
FD&C Act sections 301(a) and (d), 21 U.S.C. § 331(a) and (d)The company advertised that its products can prevent, treat, or cure disease without competent and reliable scientific evidence.
FTC Act, 15 U.S.C. § 41 et seq.Deceptive COVID-19 treatment, cure, prevention, or mitigation claims can carry civil penalties under the COVID-19 Consumer Protection Act.
COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260
What FDA wants
FDA tells the company to stop selling any unapproved or unauthorized COVID-19 products immediately and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken and how it will prevent recurrence.
Who should pay attention
- online herbal and supplement sellers
- marketplaces and social media sellers making health claims
- regulatory teams reviewing COVID-19 and disease claims
This is a summary. Read the original letter on fda.gov.